AbbVie on
Looking for more news from AbbVie? Follow us on social media.
Press Kits
 |
Our press kits are designed to provide journalists with a broad range of background information on our company.
Image library
 |
Our media library provides you with our official AbbVie media including our logo, building and leaders.
Subscribe
News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Your search returned 1000 results
-
February 15, 2018
-
February 12, 2018- Fourteen presentations of HUMIRA® (adalimumab) and pipeline data demonstrate AbbVie's extensive dermatology portfolio and continued commitment to patients living with immune-mediated diseases
-
January 26, 2018- Reports Full-Year Diluted EPS of $3.30 on a GAAP Basis; Adjusted Diluted EPS of $5.60 Reflects Growth of 16.2 Percent
-
January 12, 2018
-
January 08, 2018- Breakthrough Therapy Designation is granted to investigational treatments for serious diseases with preliminary clinical evidence that the treatment may demonstrate substantial improvement over existing therapies (1)
-
December 20, 2017
-
December 20, 2017- SELECT-MONOTHERAPY, the third study in the robust SELECT program, showed positive results, with both doses (15 mg and 30 mg once-daily) meeting the primary endpoints in patients with an inadequate response to methotrexate(1)
-
December 12, 2017- Phase 3 MURANO results presented for the first time today as one of six late breaking abstracts during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, GA
-
December 11, 2017- Clinical results suggest that ibrutinib inhibits B cells and follicular helper T cells believed to play a critical role in treating chronic graft-versus-host disease (cGVHD), while preserving immune memory and Th1 T cells
-
December 09, 2017- Nearly half of all R/R MCL patients in the pooled analysis were able to survive their disease at three years and more than one quarter of patients had no progression in their disease
-
December 09, 2017- Follow-up data from RESONATE™-2 suggest long-term benefits of ibrutinib as a first-line therapy in CLL, via the longest patient-reported outcomes to date and a progression-free survival rate of 85 percent
-
December 05, 2017- The iNNOVATE study included newly and previously-treated patients with Waldenström's macroglobulinemia (WM) and will support discussions with regulatory authorities
-
December 04, 2017- Risankizumab met all co-primary and ranked secondary endpoints in fourth pivotal Phase 3 study; no new safety signals detected across the Phase 3 program for plaque psoriasis1-4*
-
November 21, 2017- Full results from investigational Phase 3 MURANO study of venetoclax in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) to be presented for the first time in late-breaking session
-
November 03, 2017
-
November 01, 2017- In two extension studies, elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse
-
October 27, 2017- Reports Third-Quarter Diluted EPS of $1.01 on a GAAP Basis; Adjusted Diluted EPS of $1.41, Reflecting Growth of 16.5 Percent
-
October 27, 2017
-
October 27, 2017- FDA grants priority review to medicines it determines have potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease
-
October 26, 2017- First Phase 3 clinical trials reported positive results for risankizumab with 12-week dosing; no new safety signals detected across the Phase 3 program for plaque psoriasis 1,2,3
-
October 24, 2017- Thirty-eight presentations of HUMIRA® (adalimumab) and pipeline data demonstrate AbbVie's extensive immunology portfolio and continued commitment to patients living with immune-mediated inflammatory diseases
-
October 24, 2017- Collaboration combines Alector's immuno-neurology discovery platform and AbbVie's extensive research, development and commercial expertise to advance innovative new therapies for Alzheimer's disease
Who we are
 |
Get to know the passionate people who make up AbbVie and the difference we strive to make, one patient at a time. Learn more
Sustainability
 |
Our commitment to science is a commitment to better our society. Read our 2025 ESG report
Key Facts
 |
Get a closer look at our impact.
Learn more
Annual report
 |
See our latest 2025 Annual Report on Form 10-K. Learn more
